Ascorbic Acid inhibits development of tolerance and dependence to opiates in mice: possible glutamatergic or dopaminergic modulation.
In a recent study, it has been demonstrated that ascorbic acid possessed antidopaminergic activity and modulate the glutamatergic neurotransmission in mice. With this background, the present study was undertaken to study the effect of ascorbic acid on the development of tolerance and dependence to opiate and its mechanism of action. Male Swiss mice weighing 20-25 g were used in the present study. Mice were made physically dependent on opioid by the chronic administration of morphine (10 mg/kg, twice a day, for 9 days) intraperitoneally. Ascorbic acid, haloperidol (dopamine antagonist) or MK 801 (NMDA receptor antagonist) was administered daily for 9 d before challenging the animals with morphine. The development of tolerance was assessed by noting the tail-flick latency on day 1, 3, 9 and 10. On the 10(th) day after the measurement of tail-flick latency, animals were challenged with naloxone (2 mg/kg., i.p.) and incidence of escape jumps were recorded by placing the animals in 45 cm high plexiglass container. Ascorbic acid (400-1600 mg/kg) dose dependently inhibited development of tolerance and dependence to morphine as noted from tail-flick latency. When given along with MK 801 (0.01 mg/kg., i.p) or haloperidol (0.1 mg/kg i.p.), ascorbic acid (800 mg/kg., i.p.) potentiated the response of MK 801 or haloperidol. In conclusion, it is hypothesized that inhibition of development of tolerance and dependence to morphine by ascorbic acid appears to have two components, namely dopaminergic and glutamatergic.
Kulkarni
S K
SK
Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh - 160 014, India.
Deshpande
C
C
Dhir
A
A
Indian J Exp Biol. 1993 May;31(5):435-9
8359850
Psychopharmacologia. 1973;32(2):113-20
4796281
Life Sci. 1975 Jul 1;17(1):35-40
238090
Science. 1991 Jan 4;251(4989):85-7
1824728
Neuropharmacology. 1983 Aug;22(8):939-43
6312359
Science. 1985 Jan 25;227(4685):438-40
4038426
Brain Res. 1991 Apr 26;547(1):77-81
1860074
Pharmacology. 2006;77(1):38-45
16569938
Neuroreport. 1990 Nov-Dec;1(3-4):194-6
1983355
Life Sci. 1992;51(12):921-30
1355577
Gen Pharmacol. 1995 Jan;26(1):131-6
7713352
Life Sci. 1989;45(7):599-606
2671566
Neurosci Lett. 1984 Dec 21;52(3):227-33
6521967
Pharmacol Rev. 1994 Sep;46(3):293-324
7831382
Life Sci. 1980 Jul 21;27(3):185-8
7401932
Neuropharmacology. 1983 Jan;22(1):135-7
6843783
Eur J Pharmacol. 1991 May 2;197(1):9-16
1832640
Life Sci. 1978 Jan;22(1):133-6
564436
Life Sci. 1976 Jan 15;18(2):163-7
943681
Nature. 1978 Nov 9;276(5684):186-8
216919
Brain Res. 1994 Mar 14;639(2):269-74
7911390
Psychopharmacology (Berl). 2005 Aug;181(1):71-9
15806417